It costs money to make money. Most people know that the old adage is true. But it does not necessarily cost a lot of money to make good, a lot of money.
Even an initial investment of $ 3,000 can grow to a substantial sum over time. The trick is to find the right opportunities to invest. Buying shares has proven to be a great way to generate enormous returns in the long run.
But what stocks are good candidates to make a lot of money without having a lot of money to invest? Investing $ 3,000 in these three stocks can make you a fortune over the next decade.
Image Source: Getty Images.
1. Quick: Leading on the edge
Here is a number to keep in mind: 75%. That is the percentage of Internet applications that will be built by companies instead of purchased in the coming years, according to market researcher International Data Corporation. It is also the percentage of data that IDC expects to be processed at the edge of the cloud (the point where corporate networks connect to the cloud) by 2022. One company is uniquely ready to benefit from this scheme – Curse (NYSE: FSLY).
Rapidly provides an edge cloud platform for software developers that is secure, scalable, cost-effective and fast. The technology has quickly become a favorite for many of the most innovative Internet companies in the world, including Alphabet, Microsoft, Shopify, en Slap.
The company currently claims well below 1% of an addressable market that stands at more than $ 35 billion and continues to expand. But Fastly’s sales are increasing at a compound annual growth rate of 45%. Fastly’s growth will be largely driven by the growth of its existing customers. It also plans to continue launching new products and move on to international markets. The technical share should be a huge winner over the next 10 years, as it captures more of the edge platform’s rapidly growing market.
2. Guardant Health: use the power of DNA
Genetic research transforms how cancer is treated. It also changes how cancer is diagnosed. Liquid biopsies are tests that detect cancer by finding DNA fragments of tumors in the blood. These tests have the potential to save lives by enabling an early diagnosis of cancer. Guardant Health (NASDAQ: GH) stands out as a clear leader in the liquid biopsy market.
Guardant Health sells two liquid biopsy products that are already hugely successful. Guardant360 was the first comprehensive liquid biopsy to gain approval for Food and Drug Administration. Used for the genomic profiling of all types of solid tumors, it helps patients fit in with the most appropriate cancer therapy. GuardantOMNI helps drug makers screen patients for clinical trials evaluating experimental cancer drugs.
The COVID-19 pandemic has slowed the growth of Guardant Health a bit, but the company’s long-term prospects remain clear. The estimated potential U.S. market for Guardant360 is about $ 6 billion. There is a much larger address market of over $ 45 billion for Guardian Health LUNAR liquid biopsies, which are being evaluated in clinical trials for use in the early detection of cancer and monitoring of cancer recruitment.
Novavax: A donkey against the coronavirus vaccine
The US Government’s Operation Warp Speed (OWS) initiative has primarily funded the COVID-19 vaccine programs of major drugmakers. But one small biotech that could be a dark horse in the race to develop a coronavirus vaccine raised $ 1.6 billion in funding from OWS. That is biotech Novavax (NASDAQ: NVAX).
Novavax recently launched a Phase 2 study of its COVID-19 vaccine candidate, NVX-CoV2373. Some analysts refer to the research vaccine as potentially best in class after the company reported results of phase 1 tests. Novavax hopes to report interim results from its late-stage NVX-CoV2373 study in the fourth quarter of 2020.
If NVX-CoV2373 wins regulatory approval, it could be a major player in an estimated $ 20 billion global market for coronavirus vaccines. The company also plans to seek FDA approval for another potential candidate, flu vaccine NanoFlu, which could generate a maximum annual sales of up to $ 1.7 billion if approved. These are massive opportunities for a biotech with a market cap of about $ 7 billion.
